Fig. 1From: A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitorsSurvival of the patients according to the risk groups. Kaplan-Meier curves illustrating overall survival (OS) (a) and progression-free survival (PFS) (b) according to the risk groups among all the patients included in the risk modelBack to article page